Halozyme Therapeutics, Inc. $HALO Shares Newly Bought by Signal Advisors Wealth LLC

Signal Advisors Wealth LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,696 shares of the biopharmaceutical company’s stock, valued at approximately $850,000.

A number of other hedge funds have also made changes to their positions in the stock. CoreCap Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 150 shares during the period. Twin Capital Management Inc. increased its stake in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the period. First Citizens Bank & Trust Co. increased its stake in Halozyme Therapeutics by 2.0% in the 1st quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 175 shares during the period. Nations Financial Group Inc. IA ADV increased its stake in Halozyme Therapeutics by 1.2% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock valued at $981,000 after buying an additional 183 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in Halozyme Therapeutics by 0.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 202 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HALO. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday. TD Cowen upped their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.50.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew Posard sold 5,230 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the sale, the director directly owned 53,609 shares in the company, valued at $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock worth $13,538,046 over the last ninety days. 2.50% of the stock is currently owned by insiders.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks upgraded HALO from “Hold” to “Strong Buy,” providing a fresh endorsement of the company’s growth outlook and potentially attracting additional buying interest.
• Positive Sentiment: TD Cowen raised its price target to $130 from $105 while maintaining a Buy rating. The higher target suggests analysts see further appreciation potential after the stock’s recent rally. TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics Stock
• Positive Sentiment: FDA approval of Roche’s Tecentriq Hybreza for stage III mismatch-repair-deficient colon cancer expands the commercial opportunity for a Halozyme-enabled product. The approval could support future royalty revenue, with clinical data showing a 50% reduction in recurrence or death risk versus chemotherapy alone. Partner-drug approval, patent win and bullish analyst call
• Positive Sentiment: A Dutch court injunction blocking Merck’s Keytruda SC manufacturing and sales in several European markets reduces a competitive and intellectual-property overhang for Halozyme’s technology.
• Positive Sentiment: Zacks highlighted Halozyme’s solid growth characteristics as a reason growth investors should not overlook the stock. Three reasons growth investors should not overlook Halozyme
• Neutral Sentiment: Institutional positioning was mixed: 354 investors added HALO shares while 266 reduced their holdings. This indicates continued interest but also some profit-taking and portfolio rebalancing.
• Negative Sentiment: Insider activity was a potential cautionary signal, with executives reporting sales and no purchases over the past six months. These transactions may reflect profit-taking rather than a change in business fundamentals, but they could temper sentiment after the strong advance.

Halozyme Therapeutics Stock Up 4.0%

Shares of Halozyme Therapeutics stock opened at $121.51 on Friday. The firm has a market cap of $13.79 billion, a price-to-earnings ratio of 23.70, a P/E/G ratio of 0.44 and a beta of 0.88. The stock has a 50-day simple moving average of $108.68 and a 200-day simple moving average of $84.66. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $122.33. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the company posted $1.54 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.